FDA OKs for Use Noninvasive Stool Sample Test to Help Diagnose IBD

FDA OKs for Use Noninvasive Stool Sample Test to Help Diagnose IBD
Bühlmann Laboratories has received 510(k) clearance from the U.S. Food and Drug Administration (FDA) to market its noninvasive fCAL Elisa test, which uses a stool sample to help diagnose inflammatory bowel disease (IBD). fCAL Elisa is specifically designed to help physicians, in combination with other laboratory and clinical tests, with diagnosing two types of IBD:  Crohn’s disease (CD) and

Knowledge is power when living with IBD.

Get access to the web’s leading IBD news & insights for as little as 16¢/day.
Subscribe or to access all post and page content.

Leave a Comment

Your email address will not be published. Required fields are marked *